Latest Breaking News On - Aashish maheshwari - Page 5 : comparemela.com

Balaxi Pharmaceuticals reports a PAT of INR 381 million for FY21; further strengthens the Product Pipeline HYDERABAD, India, May 24, 2021 /PRNewswire/ Balaxi Pharmaceuticals Limited (Balaxi), a branded IPR-based pharmaceutical company headquartered in Hyderabad, reported its results for the quarter and year ended 31st March 2021. Financial Highlights - Q4 & FY21: 16.5% The Company recorded a revenue of INR 530 million for Q4F21, the drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday. EBITDA of INR 100 million for Q4FY21; EBITDA margin stood at 18.9%. Reported PAT of INR 84 million for Q4FY21.

United arab emiratesAndhra pradeshDominican republicEl salvadorCentral african republicAashish maheshwariSubsidiary of the companyBalaxi pharmaceuticals ltdBalaxi pharmaceuticalsShare of pharmaceuticalsPrnewswire balaxi pharmaceuticals limitedPharmaceuticals limitedChinese new yearPharmaceutical productImport permitsManaging director